- Home
- BANF vs EWTX Comparison
BANF vs EWTX Comparison
Compare BANF & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANF | EWTX |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BANF | EWTX |
|---|---|---|
| Price | $112.89 | $43.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $124.00 | $39.00 |
| AVG Volume (30 Days) | 86.6K | ★ 1.0M |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | ★ 10.40 | N/A |
| EPS | ★ 3.81 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.10 | N/A |
| Revenue Next Year | $3.92 | N/A |
| P/E Ratio | $29.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $101.48 | $13.69 |
| 52 Week High | $135.76 | $48.40 |
Technical Indicators
Market Signals| Indicator | BANF | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 45.45 |
| Support Level | $111.03 | $37.50 |
| Resistance Level | $116.03 | $45.48 |
| Average True Range (ATR) | 2.10 | 2.08 |
| MACD | -0.20 | -0.46 |
| Stochastic Oscillator | 51.33 | 16.97 |
Price Performance
Historical ComparisonAbout BANF BancFirst Corporation
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Its Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.